Churg-Strauss syndrome epidemiology and demographics: Difference between revisions

Jump to navigation Jump to search
No edit summary
 
(28 intermediate revisions by 2 users not shown)
Line 2: Line 2:
{{Churg-Strauss syndrome}}
{{Churg-Strauss syndrome}}


{{CMG}}{{APM}}{{AE}}{{KW}}
{{CMG}}{{APM}}{{AE}}{{CK}}
==Overview==
==Overview==
The prevalence of Eosinophilic granulomatosis with polyangiitis is estimated to be 10.7 per million person a year.
The [[incidence]] of [[eosinophilic granulomatosis with polyangiitis]] ranges from 2.5 to 16.6 per 100,000 individuals. [[Prevalence]]  ranges from 2 to 16 per 100,000 individuals. Mean age at [[diagnosis]] is usually around 45-50 years. In general, [[eosinophilic granulomatosis with polyangiitis]] affects men and women equally.
==Epidemiology and Demographics==
==Epidemiology and Demographics==
===Prevalence===
===Prevalence===
The prevalence of Eosinophilic granulomatosis with polyangiitis ranges from 2 to 13 per million person a year, with higher prevalences seen in Europeans.<ref name="pmid14872461">{{cite journal| author=Mahr A, Guillevin L, Poissonnet M, Aymé S| title=Prevalences of polyarteritis nodosa, microscopic polyangiitis, Wegener's granulomatosis, and Churg-Strauss syndrome in a French urban multiethnic population in 2000: a capture-recapture estimate. | journal=Arthritis Rheum | year= 2004 | volume= 51 | issue= 1 | pages= 92-9 | pmid=14872461 | doi=10.1002/art.20077 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=14872461  }} </ref>
The [[prevalence]] of [[eosinophilic granulomatosis with polyangiitis]] ranges from 2 to 16 per 100,000 individuals.<ref name="pmid15073927">{{cite journal |vauthors=Martin RM, Wilton LV, Mann RD |title=Prevalence of Churg-Strauss syndrome, vasculitis, eosinophilia and associated conditions: retrospective analysis of 58 prescription-event monitoring cohort studies |journal=Pharmacoepidemiol Drug Saf |volume=8 |issue=3 |pages=179–89 |date=May 1999 |pmid=15073927 |doi=10.1002/(SICI)1099-1557(199905/06)8:3<179::AID-PDS414>3.0.CO;2-K |url=}}</ref>


===Incidence===
The [[incidence]] of [[eosinophilic granulomatosis with polyangiitis]] range from 2.5 to 16.6 per 100,000 individuals.<ref name="pmid11926627">{{cite journal |vauthors=Loughlin JE, Cole JA, Rothman KJ, Johnson ES |title=Prevalence of serious eosinophilia and incidence of Churg-Strauss syndrome in a cohort of asthma patients |journal=Ann. Allergy Asthma Immunol. |volume=88 |issue=3 |pages=319–25 |date=March 2002 |pmid=11926627 |doi=10.1016/S1081-1206(10)62015-7 |url=}}</ref>
==Demographics==
===Age===
===Age===
The mean age at diagnosis is 50. The initial onset of symptoms may be 10-20 years earlier.
The mean age at diagnosis of [[eosinophilic granulomatosis with polyangiitis]] is around 45-50 years.


===Gender===
===Gender===
There is no gender predominance.
In general, there is no gender predilection to  [[eosinophilic granulomatosis with polyangiitis]] in western nations. In Japan, female predominance has been noted.<ref name="pmid24289197">{{cite journal |vauthors=Sada KE, Amano K, Uehara R, Yamamura M, Arimura Y, Nakamura Y, Makino H |title=A nationwide survey on the epidemiology and clinical features of eosinophilic granulomatosis with polyangiitis (Churg-Strauss) in Japan |journal=Mod Rheumatol |volume=24 |issue=4 |pages=640–4 |date=July 2014 |pmid=24289197 |doi=10.3109/14397595.2013.857582 |url=}}</ref>
 
===Race===
In general, there is no racial predominance to [[eosinophilic granulomatosis with polyangiitis]].
 
==References==
==References==
{{Reflist|2}}
{{Reflist|2}}

Latest revision as of 13:50, 10 April 2018

Churg-Strauss syndrome Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Churg-Strauss syndrome from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic study of choice

History and Symptoms

Physical Examination

Laboratory Findings

Chest X Ray

CT

MRI

Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Churg-Strauss syndrome epidemiology and demographics On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Churg-Strauss syndrome epidemiology and demographics

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Churg-Strauss syndrome epidemiology and demographics

CDC on Churg-Strauss syndrome epidemiology and demographics

Churg-Strauss syndrome epidemiology and demographics in the news

Blogs on Churg-Strauss syndrome epidemiology and demographics

Directions to Hospitals Treating Churg-Strauss syndrome

Risk calculators and risk factors for Churg-Strauss syndrome epidemiology and demographics

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Ali Poyan Mehr, M.D. [2]Associate Editor(s)-in-Chief: Chandrakala Yannam, MD [3]

Overview

The incidence of eosinophilic granulomatosis with polyangiitis ranges from 2.5 to 16.6 per 100,000 individuals. Prevalence ranges from 2 to 16 per 100,000 individuals. Mean age at diagnosis is usually around 45-50 years. In general, eosinophilic granulomatosis with polyangiitis affects men and women equally.

Epidemiology and Demographics

Prevalence

The prevalence of eosinophilic granulomatosis with polyangiitis ranges from 2 to 16 per 100,000 individuals.[1]

Incidence

The incidence of eosinophilic granulomatosis with polyangiitis range from 2.5 to 16.6 per 100,000 individuals.[2]

Demographics

Age

The mean age at diagnosis of eosinophilic granulomatosis with polyangiitis is around 45-50 years.

Gender

In general, there is no gender predilection to eosinophilic granulomatosis with polyangiitis in western nations. In Japan, female predominance has been noted.[3]

Race

In general, there is no racial predominance to eosinophilic granulomatosis with polyangiitis.

References

  1. Martin RM, Wilton LV, Mann RD (May 1999). "Prevalence of Churg-Strauss syndrome, vasculitis, eosinophilia and associated conditions: retrospective analysis of 58 prescription-event monitoring cohort studies". Pharmacoepidemiol Drug Saf. 8 (3): 179–89. doi:10.1002/(SICI)1099-1557(199905/06)8:3<179::AID-PDS414>3.0.CO;2-K. PMID 15073927.
  2. Loughlin JE, Cole JA, Rothman KJ, Johnson ES (March 2002). "Prevalence of serious eosinophilia and incidence of Churg-Strauss syndrome in a cohort of asthma patients". Ann. Allergy Asthma Immunol. 88 (3): 319–25. doi:10.1016/S1081-1206(10)62015-7. PMID 11926627.
  3. Sada KE, Amano K, Uehara R, Yamamura M, Arimura Y, Nakamura Y, Makino H (July 2014). "A nationwide survey on the epidemiology and clinical features of eosinophilic granulomatosis with polyangiitis (Churg-Strauss) in Japan". Mod Rheumatol. 24 (4): 640–4. doi:10.3109/14397595.2013.857582. PMID 24289197.

Template:WH Template:WS